Fig. 1: Reduced DCA is associated with poor clinical outcome in human gallbladder cancers. | Oncogene

Fig. 1: Reduced DCA is associated with poor clinical outcome in human gallbladder cancers.

From: Deoxycholic acid modulates the progression of gallbladder cancer through N6-methyladenosine-dependent microRNA maturation

Fig. 1

a Serum levels of primary free bile acid, secondary free bile acid, primary conjugated bile acid, and secondary conjugated bile acid in normal individuals and GBC patients (means ± SEM, n = 109 vs. 94; *p < 0.05). b Serum DCA levels in normal individuals compared with GA and GBC patients. c Receiver operating characteristic (ROC) curves of serum DCA and carbohydrate antigen 19-9 (CA19-9) for the presence of GBC with the area under the ROC curve (AUROC). Measurement of serum DCA level from GBC patient in different tumor size (d) and Ki-67 (e) expression. f Kaplan–Meier survival curves of overall survival according to serum DCA level by using the online bioinformatics tool Kaplan–Meier plotter (*p < 0.05). g Multivariable analysis of hazard ratios for overall survival in GBC by using the logistic regression model. CA cholic acid, CDCA chenodeoxycholic acid, DCA deoxycholic acid, LCA lithocholic acid, GCA glycocholic acid, TCA taurocholic, GCDCA glycochenodeoxycholic acid, GUDCA glycoursodeoxycholic acid, TCDCA taurochenodeoxycholic acid, TUDCA tauroursodeoxycholic acid, GDCA glycodeoxycholic acid, TDCA taurodeoxycholic acid, GLCA glycolithocholic acid, TLCA taurolithocholic acid.

Back to article page